Rezolute, Inc. (RZLT)

4.58 +0.04 (+0.88%) USD  |  NASDAQ  |  Sep 04, 16:00
4.575 0.00 (0.00%) Pre-Market: 20:00
More

Rezolute SG&A Expense (TTM) : 27.48M for March 31, 2026

SG&A Expense (TTM) Chart

View SG&A Expense (TTM) for RZLT.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View SG&A Expense (TTM) Chart
Start Trial

Historical SG&A Expense (TTM) Data

View and export this data back to 2012. Start Trial.
Date Value
March 31, 2026 27.48M
December 31, 2025 26.27M
September 30, 2025 20.85M
June 30, 2025 18.37M
March 31, 2025 17.39M
December 31, 2024 16.46M
September 30, 2024 15.17M
June 30, 2024 14.68M
March 31, 2024 13.97M
December 31, 2023 13.07M
September 30, 2023 13.36M
June 30, 2023 12.18M
March 31, 2023 11.60M
December 31, 2022 10.75M
September 30, 2022 10.00M
June 30, 2022 9.356M
March 31, 2022 8.878M
December 31, 2021 8.535M
September 30, 2021 8.494M
June 30, 2021 7.907M
March 31, 2021 6.767M
December 31, 2020 6.379M
September 30, 2020 5.405M
June 30, 2020 6.071M
March 31, 2020 6.385M
Date Value
December 31, 2019 6.963M
September 30, 2019 7.133M
June 30, 2019 6.82M
March 31, 2019 9.652M
December 31, 2018 10.19M
September 30, 2018 10.68M
June 30, 2018 11.45M
March 31, 2018 10.33M
December 31, 2017 9.822M
September 30, 2017 9.298M
June 30, 2017 8.229M
March 31, 2017 6.327M
December 31, 2016 5.780M
September 30, 2016 5.509M
June 30, 2016 5.503M
March 31, 2016 5.641M
December 31, 2015 5.245M
September 30, 2015 5.205M
June 30, 2015 5.805M
March 31, 2015 6.44M
December 31, 2014 6.922M
September 30, 2014 5.996M
June 30, 2014 5.279M
March 31, 2014 3.678M
December 31, 2013 2.765M

SG&A Expense (TTM) Range, Past 5 Years

View SG&A Expense (TTM) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

SG&A Expense (TTM) Benchmarks

View SG&A Expense (TTM) Benchmarks
Start Trial
SELLAS Life Sciences Group, Inc. 14.87M
AbbVie, Inc. 14.67B
Marker Therapeutics, Inc. 4.244M
Avalo Therapeutics, Inc. 27.06M
Krystal Biotech, Inc. 159.89M